Mereo Biopharma (MREO)
NASDAQ:MREO
Want to see MREO full AI Analyst Report?
Total Valuation
Mereo Biopharma Group Plc has a market cap or net worth of $45.12M. The enterprise value is $8.90M.
Market Cap$45.12M
Enterprise Value$8.90M
Share Statistics
Mereo Biopharma Group Plc has 159,618,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding159,618,600
Owned by Insiders0.81%
Owned by Institutions37.27%
Financial Efficiency
Mereo Biopharma Group Plc’s return on equity (ROE) is -1.02 and return on invested capital (ROIC) is -91.49%.
Return on Equity (ROE)-1.02
Return on Assets (ROA)-0.91
Return on Invested Capital (ROIC)-91.49%
Return on Capital Employed (ROCE)-0.92
Revenue Per Employee13.89K
Profits Per Employee-1.16M
Employee Count36
Asset Turnover0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Mereo Biopharma Group Plc is ―. Mereo Biopharma Group Plc’s PEG ratio is 0.14.
PE Ratio―
PS Ratio132.86
PB Ratio1.62
Price to Fair Value1.62
Price to FCF-2.14
Price to Operating Cash Flow-1.68
PEG Ratio0.14
Income Statement
In the last 12 months, Mereo Biopharma Group Plc had revenue of 500.00K and earned -41.88M in profits. Earnings per share was -0.26.
Revenue500.00K
Gross Profit367.00K
Operating Income-38.26M
Pretax Income-41.88M
Net Income-41.88M
EBITDA-40.47M
Earnings Per Share (EPS)-0.26
Cash Flow
In the last 12 months, operating cash flow was -26.95M and capital expenditures -1.52K, giving a free cash flow of -26.96M billion.
Operating Cash Flow-26.95M
Free Cash Flow-26.96M
Free Cash Flow per Share-0.17
Dividends & Yields
Mereo Biopharma Group Plc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.16
52-Week Price Change-87.41%
50-Day Moving Average0.31
200-Day Moving Average1.14
Relative Strength Index (RSI)50.56
Average Volume (3m)1.69M
Important Dates
Mereo Biopharma Group Plc upcoming earnings date is Aug 18, 2026, TBA (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
Mereo Biopharma Group Plc as a current ratio of 10.46, with Debt / Equity ratio of 0.00%
Current Ratio10.46
Quick Ratio10.46
Debt to Market Cap<0.01
Net Debt to EBITDA1.01
Interest Coverage Ratio-150.03
Taxes
In the past 12 months, Mereo Biopharma Group Plc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Mereo Biopharma Group Plc EV to EBITDA ratio is -0.63, with an EV/FCF ratio of -0.83.
EV to Sales51.28
EV to EBITDA-0.63
EV to Free Cash Flow-0.83
EV to Operating Cash Flow-0.83
Balance Sheet
Mereo Biopharma Group Plc has $36.22M in cash and marketable securities with $0.00 in debt, giving a net cash position of $36.22M billion.
Cash & Marketable Securities$36.22M
Total Debt$0.00
Net Cash$36.22M
Net Cash Per Share$0.23
Tangible Book Value Per Share$0.25
Margins
Gross margin is 12.50%, with operating margin of -7651.40%, and net profit margin of -8375.60%.
Gross Margin12.50%
Operating Margin-7651.40%
Pretax Margin-8375.60%
Net Profit Margin-8375.60%
EBITDA Margin-8094.80%
EBIT Margin-8324.60%
Analyst Forecast
The average price target for Mereo Biopharma Group Plc is $2.33, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.33
Price Target Upside586.27% Upside
Analyst ConsensusModerate Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast28.17%